Desvenlafaxine Succinate(des ven la fax’ een)
PristiqDNC
PREGNANCY CATEGORY C
Drug Classes
Antidepressant
Serotonin-norepinephrine reuptake inhibitor
Therapeutic Actions
Potentiates the neurotransmitter activity in the CNS; inhibits serotonin and norepinephrine reuptake at the nerve synapse, leading to prolonged stimulation at the neuroreceptor; this action is thought to decrease the signs and symptoms of depression.
Indications
Treatment of major depressive disorder in adults
Contraindications and Cautions
Contraindicated with known hypersensitivity to any component of the drug or venlafaxine, with use of an MAOI, or within 14 days of stopping an MAOI.
Use cautiously with hypertension, glaucoma, abnormal bleeding, use of drugs that alter coagulation, vascular disease, lipid disorders, renal impairment, lung disease, pregnancy, lactation.
Available Forms
ER tabletsDNC—50, 100 mg
Dosages
Adults
50 mg/day PO with or without food; range, 50–400 mg/day.
Pediatric patients
Safety and efficacy not established.
Patients with renal impairment
For CrCl of 30–50 mL/min, dose should not exceed 50 mg/day PO; for CrCl of less than 30 mL/min or end-stage renal disease, dose is 50 mg PO every other day. Do not administer supplemental dose after dialysis.
Pharmacokinetics
|
Metabolism: Hepatic; T1/2: 11 hr
Distribution: May cross placenta, enter breast milk
Excretion: Urine
Adverse Effects
CNS: Dizziness, headache, somnolence, tremor, paresthesia, insomnia, anxiety, nervousness, irritability, abnormal dreams, suicidal ideation, vision impairment, tinnitus, glaucoma, activation of bipolar symptoms
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
